Table 1.
Study demographics
| Total (n = 42) | Non-ICDs (n = 18) | ICDs/CRT-Ds (n = 24) | p-value | |
|---|---|---|---|---|
| Age (years) | 62.5 [51–69] | 60 [41–69] | 66 [52–71.5] | 0.226 |
| Males % | 25 (60%) | 7 (39%) | 18 (75%) | 0.027* |
| BMI (kg/m2) | 29.6 [25.5–31.8] | 27.85 [22.8–30.5] | 30.45 [26.85–33.05] | 0.131 |
| Etiology | ||||
| ICM | 11 (26%) | 5 (28%) | 6 (25%) | 0.731 |
| NICM | 31 (74%) | 13 (72%) | 18 (75%) | 0.731 |
| ARVC | 5 (12%) | 2 (11%) | 3 (13%) | 1.000 |
| Valvular heart disease | 3 (7%) | 2 (11%) | 1 (4%) | 0.567 |
| HCM | 2 (5%) | 1 (6%) | 1 (4%) | 1.000 |
| Sarcoid | 2 (5%) | 0 (0%) | 2 (8%) | 0.508 |
| Idiopathic | 19 (45%) | 9 (50%) | 10 (42%) | 0.756 |
| LVEF % | 50 [35–60] | 57 [50–60] | 44.5 [30–52.5] | 0.007* |
| NYHA | 0.017* | |||
| Class I | 23 (55%) | 14 (78%) | 9 (38%) | |
| Class I | 15 (36%) | 4 (22%) | 11 (46%) | |
| Class III | 4 (10%) | 0 | 4 (16%) | |
| Class IV | 0 | 0 | 0 | |
| Diuretics | 18 (43%) | 2 (11%) | 16 (67%) | 0.001* |
| COPD | 1 (2%) | 1 (6%) | 0 | 0.429 |
| OSA | 10 (24%) | 3 (17%) | 7 (29%) | 0.473 |
| Atrial fibrillation | 13 (31%) | 4 (22%) | 9 (38%) | 0.333 |
Continuous variables are reported as median and inter-quartile range. ARVC/ARVD Arrhythmogenic right ventricular cardiomyopathy, BMI Body mass index, COPD Chronic obstructive pulmonary disease, HCM Hypertrophic cardiomyopathy, BMI Body Mass Index, LVEF Left ventricular ejection fraction, NICM Non-ischemic cardiomyopathy, NYHA New York heart association, OSA Obstructive sleep apnea
(*) Statistically significant